Egypt's NUCA, SHMFF sign New Cairo land allocation for integrated urban project    CIB named Egypt's Bank of the Year 2025 as factoring portfolio hits EGP 4bn    Egypt declares Red Sea's Great Coral Reef a new marine protected area    Oil prices edge higher on Thursday    Gold prices fall on Thursday    Egypt, Volkswagen discuss multi-stage plan to localise car manufacturing    Egypt denies coordination with Israel over Rafah crossing    Egypt to swap capital gains for stamp duty to boost stock market investment    Egypt tackles waste sector funding gaps, local governance reforms    Egypt, Switzerland explore expanded health cooperation, joint pharmaceutical ventures    Egypt recovers two ancient artefacts from Belgium    Private Egyptian firm Tornex target drones and logistics UAVs at EDEX 2025    Egypt opens COP24 Mediterranean, urges faster transition to sustainable blue economy    Egypt's Abdelatty urges deployment of international stabilisation force in Gaza during Berlin talks    Egypt, Saudi nuclear authorities sign MoU to boost cooperation on nuclear safety    Giza master plan targets major hotel expansion to match Grand Egyptian Museum launch    Australia returns 17 rare ancient Egyptian artefacts    China invites Egypt to join African duty-free export scheme    Egypt calls for stronger Africa-Europe partnership at Luanda summit    Egypt begins 2nd round of parliamentary elections with 34.6m eligible voters    Egypt warns of erratic Ethiopian dam operations after sharp swings in Blue Nile flows    Egypt scraps parliamentary election results in 19 districts over violations    Egypt extends Ramses II Tokyo Exhibition as it draws 350k visitors to date    Egypt signs host agreement for Barcelona Convention COP24 in December    Al-Sisi urges probe into election events, says vote could be cancelled if necessary    Filmmakers, experts to discuss teen mental health at Cairo festival panel    Cairo International Film Festival to premiere 'Malaga Alley,' honour Khaled El Nabawy    Egypt golf team reclaims Arab standing with silver; Omar Hisham Talaat congratulates team    Egypt launches National Strategy for Rare Diseases at PHDC'25    Egypt launches Red Sea Open to boost tourism, international profile    Omar Hisham Talaat: Media partnership with 'On Sports' key to promoting Egyptian golf tourism    Sisi expands national support fund to include diplomats who died on duty    Egypt's PM reviews efforts to remove Nile River encroachments    Egypt resolves dispute between top African sports bodies ahead of 2027 African Games    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



GSK outperforms market expectations
Aya Anwar Published in Amwal Al Ghad on 31 - 01 - 2024

GSK outperformed market expectations for its fourth-quarter results on Wednesday and released an optimistic outlook for 2024 as the pharmaceutical company increases the number of vaccines, infectious disease and cancer drugs it is developing.
This is the company's first annual report on earnings following its July 2022 spinoff of the consumer healthcare division, Haleon.
Since then, the London-listed company has focused more intently on immunisations and infectious diseases, and GSK has tried to strengthen its drug pipeline with the $7 billion that the spin-off produced.
Furthermore, the market's concerns regarding GSK's drug development pipeline and the expensive litigation surrounding the discontinued heartburn medication Zantac in the United States have been allayed by the robust uptake of the respiratory syncytial virus (RSV) vaccine Arexvy.
After a second-half launch, Arexvy recorded sales of 1.24 billion pounds for the year that concluded on December 31.
"We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology," CEO Emma Walmsley stated.
Based on sales growth of 5-7 per cent, GSK anticipates an increase in adjusted profit per share of between 6 per cent and 9 per cent in 2024. This growth is comfortably above analysts' growth expectations, according to a poll provided by the company.
By 2026, the company anticipates that sales will have grown by more than 7 per cent annually, up from an earlier forecast of 5 per cent.
LSEG data shows that on sales of 8.05 billion pounds ($10.20 billion), it reported a profit of 28.9 pence per share, compared with analysts' average expectations of 28.63 pence profit on sales of 7.29 billion pounds.
($1 = 0.7892 pounds)

Clic here to read the story from its source.